Clinical trials: B Cell
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did…
- Trial name
- NCT02034227
- Testing
- SG2000
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spirogen
Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
- Conditions
- Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
- Trial name
- NCT06116110
- Testing
- Long-term Follow-Up
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Miltenyi Biomedicine GmbH
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Diphtheria, Hepatitis B
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
The purpose of the study is to demonstrate consistent results in 3 production lots of Hib-MenAC vaccine when extemporaneously mixed with Tritanrix™-HepB and administered as a single injection, with respect to immunogenicity…
- Conditions
- Diphtheria, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis
- Trial name
- NCT00317161
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia, Richter Syndrome
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
- Trial name
- NCT02535286
- Testing
- Umbralisib, ublituximab, TG-1501
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- TG Therapeutics, Inc.
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
This is an open-label, Phase I study to determine the highest amount of the study drug, ON 01910.Na, that can be safety given to patients with high risk myelodysplastic syndromes (MDS) or refractory leukemias.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00854646
- Testing
- ON 01910.Na
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Traws Pharma, Inc.
Lymphoma, Non-Hodgkin
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
The purpose of this phase II open label study was is to evaluate the safety and efficacy of ofatumumab and bendamustine followed by maintenance ofatumumab in subjects with indolent B-NHL who had relapsed after Rituximab…
- Trial name
- NCT01294579
- Testing
- Ofatumumab, Bendamustine
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
B Cell Lymphoma
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
This is a multicenter, randomized, double-blind, parallel group study to compare the PK, safety, tolerability, immunogenicity and PD of JHL1101 vs Rituxan in subjects with CD20-positive B cell lymphoma.
- Trial name
- NCT03670888
- Testing
- JHL1101, Rituximab
- Where
- 2 sites in China
- Volunteers
- 1 people
- Sponsor
- JHL Biotech, Inc.
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Acute Lymphoblastic Leukemia
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma.
- Trial name
- NCT02369653
- Testing
- Apixaban, No systemic anticoagulant prophylaxis
- Where
- 96 sites in United States, Australia and 10 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
B-cell Malignancies
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study.
- Trial name
- NCT04170283
- Testing
- Zanubrutinib, Tislelizumab
- Where
- 153 sites in United States, Australia and 16 more
- Volunteers
- 955 people
- Sponsor
- BeOne Medicines
Non Hodgkin Lymphoma
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin…
- Trial name
- NCT06088654
- Testing
- IPH6501
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 23 people
- Sponsor
- Innate Pharma
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors, Chronic Lymphocytic Leukemia
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
This is a four-part dose-escalation and confirmation study in participants with advanced solid tumors. Part A is for dose escalation and determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of…
- Conditions
- Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia
- Trial name
- NCT00749502
- Testing
- MK-4827
- Volunteers
- 113 people
- Sponsor
- Tesaro, Inc.
T-Cell Lymphoma, B-Cell Lymphoma
A Study for Patients With Non-Hodgkin's Lymphomas
In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma.
- Trial name
- NCT00542919
- Testing
- enzastaurin
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 57 people
- Sponsor
- Eli Lilly and Company
Liver Cirrhosis
Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.
- Trial name
- NCT05106972
- Testing
- UC-MSC infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.